NeuroDiscovery makes market debut
Monday, 15 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
NeuroDiscovery's IPO raised AUD$1.5 million through the issue of 36 million shares, and the company has finalised purchase of UK-based NeuroSolutions, which has a mature pipeline of programs for the treatment of pain.
"We are very pleased that we have been able to buy NeuroSolutions and welcome the University of Warwick as our major shareholder. As this is the first successful spin-out of the university we look forward to working with them in the next few years." said NeuroDiscovery chairman David McAuliffe.
At the time of writing, shares were trading at $0.20.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
